Related Experiment Videos
Human antibodies by design
T J Vaughan1, J K Osbourn, P R Tempest
1Cambridge Antibody Technology, Melbourn, Cambridgeshire, UK. tris.vaughan@camb-antibody.co.uk
Nature Biotechnology
|June 13, 1998
Summary
Fully human monoclonal antibodies (mAbs) are crucial for effective therapy, overcoming immune rejection seen with rodent-derived versions. Advances in phage display and transgenic mice are enabling the production of these advanced therapeutic antibodies.
Area of Science:
- Biotechnology
- Immunology
- Pharmacology
Background:
- Monoclonal antibodies (mAbs) are valuable therapeutics due to their natural role and low toxicity.
- Rodent-derived mAbs face limitations in clinical use because of patient immune responses.
- Chimerized and humanized mAbs represent progress, but fully human antibodies are the next frontier.
Purpose of the Study:
- To discuss the development and potential of fully human monoclonal antibodies.
- To highlight advancements in generating human mAbs for therapeutic applications.
Main Methods:
- Phage display technology for generating human antibody libraries.
- Transgenic mouse models for producing human antibodies.
- Clinical trials of fully human mAbs from phage display.
Main Results:
- Fully human mAbs are now producible through phage display and transgenic mice.
- Phage display-derived fully human mAbs have entered clinical trials.
- These technological advances are paving the way for the full therapeutic potential of antibodies.
Conclusions:
- The development of fully human monoclonal antibodies is essential for overcoming immunogenicity issues.
- Phage display and transgenic mouse technologies are key to producing safe and effective human mAbs.
- These advancements promise to unlock the complete therapeutic potential of antibody-based treatments.